NIPH Clinical Trials Search

A Single and Multiple Dose Study of MK-6916 in Healthy Japanese Participants

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Pain
Date of first enrollment	24/02/2026
Target sample size	32
Countries of recruitment
Study type	Interventional
Intervention(s)	Panel A: MK-6916 50mg, 200mg, or 50mg (fed condition) administered as a single oral dose. Panel B: MK-6916 100mg or 400mg administered as a single oral dose. Panel C: MK-6916 300mg administered orally every 24 hours for 10 days. Panel D: MK-6916 150mg administered orally every 12 hours for 10 days.

Outcome(s)

Primary Outcome	Adverse events, discontinuation of study intervention due to adverse event(s).
Secondary Outcome	Pharmacokineticks

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	<= 55age old
Gender	Both
Include criteria	Healthy male participants and female participants of nonchildbearing potential between the ages of 18 and 60 years
Exclude criteria	Has a history of clinically significant abnormalities or diseases